The state of antiviral therapies is currently lacking in effectiveness compared to treatments for bacterial infections. Existing antiviral drugs either act as vaccines or only partially disrupt the viral life cycle. This limitation hinders the ability to combat age-related dysfunctions caused by persistent viral infections.
One ray of hope in the antiviral landscape was the DRACO technology, developed to selectively kill cells infected with viruses. While initial results showed promise, the research program faced funding challenges and stalled. However, Kimer Med, a New Zealand biotech startup, has stepped in to advance the technology independently. After years of progress, they are now on the brink of clinical trials with an improved version of DRACO.
What happened to DRACO?
When Dr. Todd Rider introduced DRACO in 2011, it garnered significant attention for its potential to combat various viruses effectively. However, the lack of funding hindered the progress of this groundbreaking discovery. Enter Kimer Med, founded during the COVID-19 pandemic, which has made remarkable advancements in refining and expanding the scope of Rider’s work.
With a platform for developing broad-spectrum antivirals, Kimer Med has demonstrated success against multiple viruses, offering hope for the treatment of a wide range of viral infections. While a cure-all for viruses may not be feasible, the prospect of tailored antiviral treatments holds promise for addressing a spectrum of viral challenges.
Kimer Med’s innovative approach not only targets viral replication but also enhances the body’s immune response to eliminate infected cells. By focusing on a common denominator in viral infections, they aim to address unmet medical needs and advance antiviral therapies to clinical trials, where past efforts faltered.
